ABSTRACT
INTRODUCTION T H E A D O P TIV E TR A N S F ER of sensitized T cells has been
demonstrated to mediate the regression of advanced tumors in a variety of animal models (Rosenberg et al., 1986; Chou et al., 1988a) . A major obstacle that confronts the clinical application of adoptive immunotherap y is the relatively weak immunogenicity of human cancers, as well as tumor-induced immunosuppression , which hampers the induction of immune effector T cells. We have concentrated on developing methods to generate and expand immune T cells from either tumor-draining or vaccine-prim ed lymph nodes (VPLNs) (Chou et al., 1988b; Shu et al., 1989; Yoshizawa et al., 1991; Geiger et al., 1993) . These lymph nodes harbor "preeffector" T cells that can be preferentially activated by a variety of in vitro methods and subsequently transferred back to the tumor-bearing host for therapeutic benefit. We have chosen to prime lymph nodes with autologous tumor cells utilized as a vaccine in conjunction with an immune adjuvant. The use of autologous tumor cells has the advantage of vaccinating the individual with an array of antigens unique for that individual. The focus of this study was to investigate a novel method of delivering an immune adjuvant.
Observations in anim al studies have shown that tum or cells can be genetically altered to enhance the host immune response against parental tum or antigens. Various cytokine genes have been evaluated in preclinical models of gene-modified tumor cell vaccinations followed by challenge of parental cells (Fearon et al., 1990; Gansbacher et al., 1990; Asher et al., 1991; Colombo et al., 1991; Golumbek et al., 1991; Dranoff et al., 1993) . Granulocyte-m acrophage colony-stim ulating factor (GM-CSF) appears to be a superior cytokine as an adjuvant in this setting (Dranoff et al., 1993) . GM-CSF is a 23-kDa glycoprotein that was initially shown to promote the in vitro proliferation and differentiation of hematopoietic progenitors to neutrophils and macrophages. Other studies have shown that GM-CSF can also induce the generation of eosinophils, erythrocytes, and megakaryocytes (Donahue et al., 1986; Metcalf et al., 1987) . Also, GM-CSF is an important growth factor for dendritic cells (DCs), and essential for the normal function of DCs (Witmar-Pack et al., 1987; Sallusto and Lanzavecchia, 1994) . In the setting of tumor-induced immune suppression, GM-CSF can reverse the suppressed function of tumor-derived DCs (Nestle et al., 1997a) . DCs are critical in the sensitization of naive CD4
1 and CD8 1 T cells to antigen (Fields et al., 1998; Perez-Diez et al., 1998) . These properties make GM-CSF an appropriate adjuvant to use in a genetically engineered autologous tumor vaccine.
We designed a clinical trial involving melanoma patients to evaluate the adoptive transfer of activated lymph node cells primed in vivo with autologous tumor cells transduced with the GM-CSF gene. Tumor cells were derived from each patient and placed in bulk culture, during which time they were transduced by a retroviral vector. These cells were utilized as irradiated tumor cell vaccines to prime draining lymph nodes. The VPLN cells were harvested and subsequently activated by an anti-CD3/interleukin 2 (IL-2) culture method we have previously described in a prior clinical study ; and adoptively transferred into patients with the concomitant administration of IL-2. The specific aims of the protocol were to (1) assess the feasibility and toxicity of this treatment, (2) evaluate the in vitro immunological reactivities of the VPLN cells to autologous tumor, and (3) evaluate the antitumor efficacy of the therapy.
MATERIALS AND METHODS

Treatment plan
Patients with stage IV melanoma were eligible and required to have a performance status on the Eastern Cooperative Oncology Group (ECOG) scale of 0 or 1. Patients were excluded if brain metastases were detectable by computed tomography (CT) or magnetic resonance imaging (MRI). Other eligibility and exclusion criteria have been published (Chang et al., 1996) .
Patients underw ent surgical retrieval of tumor to generate the vaccine. Early-passage tumor cells were transduced with a retroviral vector containing the GM-CSF gene. The transduced cells were assayed for GM-CSF production and irradiated with 5000 cGy. Patients were vaccinated with 1-2 3 10 7 irradiated transduced tumor cells in two separate sites. In several of the patients, wild-type (WT) tumor cells were similarly irradiated and injected as a control vaccine. The control vaccine was placed at a separate site in order to retrieve VPLN from a different nodal basin. Surgical rem oval of GM-CSF VPLN and WT VPLN occurred 7 to 10 days after vaccination. The cells from the VPLN underwent ex vivo activation with anti-CD3 monoclonal antibody (MAb) and expansion in IL-2. After activation, the lymphocytes were transferred intravenously to the patient followed by the intravenous administration of IL-2 every 8 hr for 15 doses. Patients were monitored for toxicity in the General Clinical Research Center (GCRC) at the University of Michigan (Ann Arbor, MI). After therapy, the patients were assessed for tumor response at 4 and 8 weeks. If there was stable disease or evidence of tumor response, patients were retreated with cells activated from cryopreserved VPLN. Repeat treatments were continued until VPLN cells were no longer available, at which time IL-2 was adm inistered until best response was achieved. This protocol was approved by the University of Michigan Institutional Review Board, National Institutes of Health Recombinant DNA Advisory Committee, and the Food and Drug Administration (FDA).
Retroviral vector: MFG-GM-CSF
MFG-GM-CSF is a Moloney murine leukem ia virus that encodes human GM-CSF and was developed by R. Mulligan (Somatix Therapy, Alameda, CA). Somatix Therapy supplied FDA-approved clinical-grade viral particles used in this study (IND BB5229) . In this vector, Moloney murine leukemia virus (Mo-MuLV) long terminal repeat (LTR) sequences are used to generate both a full-length viral RNA necessary for the generation of viral particles and a subgenomic mRNA analogous to the Mo-MuLV env RNA, which is responsible for the expression of hum an GM-CSF (huGM-CSF. The vector retains both sequences in the viral gag region shown to improve the encapsidation of viral RNA and the normal viral 59 and 39 splice sites necessary for generation of the subgenomic RNA. DNA sequences encoding human GM-CSF have been inserted between NcoI and BamHI sites in such a way that the initiation codon of the inserted sequences is placed precisely at the position normally occupied by the initiation codon for env translation, and minim al 39 nontranslated sequences are included in the insert. Unlike many vectors comm only in use, MFG-S contains no sequences encoding a selectable marker. The psiCRIP cell line was utilized for the packaging of recombinant genomes into virus particles. High-titer stocks of recombinant viruses suitable for clinical use were generated from cultures of cells propagated in a closed-loop perfusion system designed for the mass cultures of anchorage-depend ent cells. until processing. Necrotic tumor and connective tissue were trimmed and the rem aining specim en minced into approximately 3-to 4-mm 3 pieces with scissors in Hanks' balanced salt solution (HBSS) containing hyaluronidase (2.5 units/ml), collagenase (0.5 mg/ml), and deoxyribonucleas e (0.05 mg/ml) (all obtained from Sigma, St. Louis, MO). Routinely, 1 g of tumor specimen was digested in a minimum volume of 10 ml of enzym e mixture. The resulting cell suspension was centrifuged (500 3 g, 15 min), filtered through a double layer of No. 100 nylon mesh, and resuspended in 100 ml of RPMI 1640 medium containing 10% heat-inactivated human AB serum. Aliquots of tumor cells were cryopreserved in 90% human AB serum plus 10% dimethylsulfoxi de, at 2 178°C in liquid nitrogen.
In addition to cryopreservation, tumor cells were suspended in approximately 60 ml of complete medium (CM) in 150-cm 2 flasks with 1-5 3 10 6 freshly dissociated tumor cells/flask. CM is composed of RPMI 1640 with 10% human AB serum, 2 mM glutamine, and gentamicin (50 m g/ml) (all from BioWhittaker, Walkersville, MD). Flasks were incubated at 37°C in 5% CO 2 .
Transduction of tumor cells with the MFG-S-GM-CSF viral particles
Frozen virus supernatant was thawed in preparation for tumor cell transduction. Tumor cells were plated at 0.5-1 3 10 6 cells per 75-cm 2 flask and incubated at 37°C in a 5% CO 2 incubator for 18 hr in CM. Transductions were performed by aspirating the CM and replacing it with 10 ml of MFG-S-GM-CSF viral particles containing DEAE-dextran (35 m g/ml; Sigma) and incubated for 4 hr. The viral particles were then aspirated and replaced with 14 ml of CM. GM-CSF production was assayed 24 hr later by enzyme-linked immunosorbe nt assay (ELISA). If protein production was of high-enough quantity to prepare a tumor cell vaccine (i.e., greater than 40 ng/ml/10 6 cells/ 24 hr), the cells were then washed, harvested, and used for vaccine preparation as described below. A minimum of 10 7 cells/ vaccine will be prepared, which should represent at least 400 ng of GM-CSF produced per 24 hr. The minimum level of GM-CSF production represents an equivalent amount of GM-CSF production identified in our animal model to enhance T cell sensitization in the draining LN (Arca et al., 1996a) .
Vaccination with GM-CSF-modified tumor cells
Gene-modified tumor cells were irradiated with 5000 cGy. The cell suspension was adjusted so that a volume of 0.5 ml of HBSS contained 1-2 3 10 7 irradiated tumor cells. The tumor cells were placed on ice until injection. Patients were immunized intradermally with 0.5 ml of the cell suspension in one or two separate sites drained by an accessible nodal basin (i.e., inguinal region). Lymph nodes draining the sites of vaccination were selected so that the chosen LN group did not have clinically apparent metastases. Control vaccinations with a comparable num ber of WT irradiated tum or cells were inoculated intraderm ally in a separate site.
Preparation of single cells from lymph nodes
Patients underwent excision of vaccine-draining LN 7 to 10 days after the vaccination. Identification of the immediate draining LN was aided by the intradermal inoculation of blue dye (Lymphozurin ) at the vaccine site as described by Morton et al. (1992) . Single-cell suspensions of lymph node cells were prepared mechanically by methods previously described . After washing the cells in HBSS three times, they were placed in anti-CD 3 activation cultures immediately and the remaining LN cells were cryopreserved in liquid nitrogen for subsequent analysis and possible use in retreatments.
Anti-CD3 activation and expansion
Anti-CD3 activation and expansion required culturing cells an average of 15 days and subjecting the draining LN cells to primary and secondary culture procedures as previously described . For primary anti-CD 3 activation, 5 3 10 8 lym phocytes were resuspended in serum-free medium (X-Vivo-15; BioWhittaker) at a concentration of 2 3 10 6 cells/ml and cultured in 24-well tissue culture plates (2 ml/well) pretreated with OKT3. After 48 hr of activation the cells were harvested and expanded in IL-2. Expansion was accomplished by resuspending anti-CD3-activ ated cells by diluting the primary activation medium with X-Vivo-15 supplemented with IL-2 (60 IU/ml; Chiron Therapeutics, Emeryville, CA) to a cell concentration of 3 3 10 5 cells/ml. These cells were placed in 3000-m l culture bags (Lifecell 3000; Fenwal, Deerfield, IL), each containing 500-850 ml of medium. When the cell density reached approximately 10 6 cells/ml, an additional 2 liters of serum -free X-Vivo-15 containing IL-2 (60 IU/ml) was added to each bag. Cells were grown to a maximum density (approximately 2 3 10 6 cells/ ml), which took approximately 5 days. The procedure to perform the secondary anti-CD3 activation represented a slight modification of the primary culture procedure. Briefly, 2 3 10 8 anti-CD3-activ ated cells derived from the primary culture procedure were suspended in 100 ml of fresh medium in 150-cm 2 flasks with immobilized OKT3 MAb. After 1 day, the cells were harvested, washed, and expanded in serum -free medium (X-Vivo-15) containing IL-2 (60 IU/ml), using 3000-ml culture bags as previously described. Cells were harvested after approximately 7 days, when cells had reached their maxim um density.
Adoptive cellular therapy and IL-2 administration
The lym phocytes were suspended in infusion medium, consisting of 190 ml of normal saline, 10 ml of human albumin (concentration, 25% ; final concentration, 1.25% ) and 450,000 IU of IL-2. IL-2 was administered intravenously to enhance the activity of the activated cells and was given every 8 hr for a total of 15 doses starting on the day of cell transfer. Infusion of IL-2 consisted of 360,000 IU/kg and comm enced immediately after cell transfer. This schedule and dose of IL-2 has been associated with manageable and reversible side effects according to our previous experience with this regimen . The patients were treated as inpatients in the GCRC.
Light microscopic and immunohistoche mical analysis
Besides routine light microscopic assessment of formalinfixed paraffin-embedd ed sections of tissue excised from the vaccine sites stained with hematoxylin-eosin, immunopathological examination was also performed. Serial sections of the paraffin blocks were placed on glass slides, and immunostained by a highly sensitive avidin-biotin immunoperoxidase technique with 3-amino-4-ethylc arbazole to produce a positive red reaction product. For detection of some antigens, tissue sections were microwaved in phosphate-buffer ed saline (PBS) for antigen retrieval prior to addition of primary antibodies. The following antibodies were used to detect their respective antigens: rabbit anti-serum against factor XIIIa was used to visualize dendritic cells (Calbiochem-Novabiochem, San Diego, CA); either rabbit anti-S100 or antivimentin Abs (obtained from Dako, Carpenteria, CA) were used to detect melanoma cells. Polymorphonuclear leukocytes (PMNs) and macrophages were immunostained with anti-MAC387 MAb (Dako), and distinguished by their morphology. Anti-CD 3 pan T cell MAb and anti-CD45R 0 MAb were used to detect memory-type T lymphocytes, and were purchased from Becton Dickinson (Mountain View, CA).
Detection of dermal DCs in both normal and diseased skin has been facilitated by immunostaini ng for the clotting factor XIIIa (Cerio et al., 1989) . Since the initial recognition of a population of cells in the derm is with a dendritic morphology, it has become clear that such cells can function as antigen-presenting cells, and contribute to the dermal immune system (Headington, 1993) . It is now well established that there are several different types of derm al dendritic cells, and that the subset that expresses factor XIIIa can function as professional antigen-presenting cells (Nestle et al., 1993) .
A semiquantitative assessment of the relative intensity of the cellular infiltrates was scored on a 1-5 point scale, with 11 being considered a mild degree of infiltration, 31 being considered as moderately intense, and 51 representing severely intense infiltrate for the respective cell types as determined by a single observer.
Immune functional analysis of VPLN cells
Immune reactivity of activated WT and GM-CSF VPLN cells was assessed by measurement of secretion of cytokines in response to irradiated autologous tumor cells as previously described Li et al., 1999) 
selection with paramagnetic beads as previously described (Li et al., 1999) . After T cell activation and expansion, 2 3 10 6 activated VPLN cells were cocultured with 0.5 3 10 6 irradiated autologous tum or cells in 2 ml of medium placed in individual wells of a 24-well culture plate. The assay medium consisted of RPMI 1640 supplemented with 10% fetal bovine serum , 1 mM sodium pyruvate, 13 nonessential amino acids, penicillin (100 units/ml), streptomycin (100 m g/ml), gentamicin sulfate (50 m g/ml), Fungizone (0.5 m g/ml), 0.05 mM 2-mercaptoethanol (all from BioWhittaker ), and IL-2 (4 IU/ml). Tumor cells were irradiated with 20,000 cGy using a 13 7 Cs source (500 cGy/min, gamm a cell irradiator; Atomic Energy of Canada, Mississauga, Ontario, Canada). After 48 hr, culture supernatants were collected and centrifuged at 1500 rpm for 5 min to separate any cells. Culture supernatants were then measured for interferon g (IFN-g ) , GM-CSF, and IL-10 with comm ercially available ELISA reagents (PharM ingen, San Diego, CA), according to the manufacturer directions. For GM-CSF, a standard curve starting at 20,000 pg/ml with serial twofold dilutions was performed. For IFN-g and IL-10, standard curves starting at 10,000 pg/ml were established in a similar fashion. The threshold of detection for each cytokine was approximately 100 pg/ml. Experimental values were computed after cytokine release by T cells or tumor cells alone was subtracted.
Inhibition of T cell recognition of tumor-associated antigen on target tum or cells was examined with anti-class I (HLA-A, -B, and -C) MAb and anti-class II (HLA-DR, -DP, -DQ) MAb (PharM ingen) in the cytokine release assay.
RESULTS
Transduction of tumor cells and plasma levels
A total of seven patients had tumor surgically removed and placed into tissue culture to develop proliferating cells. Approximately 3 weeks after placem ent into culture, the cells were transduced with retrovirus. Five of the seven attempts resulted CHANG ET AL. 844 in transgenic GM-CSF production by tumor cells whereas, in the remaining two patients, cell death was observed. For patients 1-5, the amount of transgenic GM-CSF protein produced by the tumor cells was 56, 86, 62, 96, and 100 ng/10 6 cells/24 hr, respectively. Between 1 3 10 7 and 2 3 10 7 irradiated tumor cells were inoculated intradermally in the anterior thigh skin. Mild induration with skin erythema was observed approximately 7-10 days later at the time of VPLN harvest. There was no skin ulceration or systemic toxicity associated with the vaccines. Plasma levels of GM-CSF were undetectable by ELISA for all patients when assessed 7-10 days after vaccination.
Vaccination sites and yield of VPLN
At the time of vaccine-primed LN removal, the intradermal vaccine sites were also excised for immunohistoch emical analysis. Antibodies were used to identify melanoma tumor cells, dendritic cells (DCs), and tissue macrophages (Mf ). Illustrations of the vaccine sites are depicted in Figs. 1 and 2 . In patient 1 (Fig. 1) , routine light microscopy revealed mild epidermal acanthosis with a prominent mid-and deep dermal mononuclear cell inflammatory infiltrate (Fig. 1A-C) . By immunohistochem ical staining, specific cell populations were identified. These included tum or cells (Fig. 1D ), which were surrounded by DCs (Fig. 1F and G) . CD45RO-positive memory cells comprised the majority of the lym phocytes within the infiltrate ( Fig. 1H and I) . No MAC387-reactiv e macrophages were present in the infiltrate. In patients 2-5, bilateral anterior thigh vaccinations were performed with one side receiving the transduced tumor cells; and the contralateral side receiving irradiated, nontransduced wild-type tumor cells. Both vaccine sites were excised at the time of LN harvest and the cellular infiltrates compared. In Fig. 2 , the vaccine sites of patient 2 are illustrated for comparison. Routine light microscopy of the nontransduced wild-type vaccine site revealed a sparse superficial and deep perivascular lymphocyte infiltrate ( Fig. 2A ). In contrast, the GM-CSF-transduced vaccine site demonstrated a dense mononuclear cell infiltrate beginning in the upper papillary dermis and extending into the deep reticular dermis (Fig.  2B-D) . This infiltrate includes lymphocytes, neutrophils, and eosinophils. By immunohistoch emical analysis, extensive DC infiltration was noted surrounding melanoma tumor cells ( Fig.  2G and H) . Again, num erous CD45RO-positive "memory" T cells were present throughout the dermis adm ixed with tumor cells (Fig. 2I and J) . Occasional MAC387-positive macrophages were present near tumor cells (Fig. 2F) .
The histologic findings are summarized in Table 1 . Patient 3 did not have an increased infiltration of DCs at the transduced vaccine site compared with the nontransduced vaccine site; this was thought to be due to the subcutaneous inoculation of the vaccine. By contrast, all of the other patients had their vaccines inoculated intradermally. As depicted in Table 1 , GM-CSF secretion consistently resulted in the infiltration of DCs to the vaccine site in the patients given an intradermal inoculation of tumor cells. Compared with the WT vaccine site, there were no differences in infiltration of PMNs or macrophages.
The yields of VPLN cells draining the different vaccine sites are also summarized in Table 1 . In all four patients into whom both WT and GM-CSF-transduced tumor cells were inoculated, there was a greater yield of VPLN cells elicited by the transduced tum or cell vaccine. The mean number (6 SEM) of GM-CSF and WT VPLN cells was 5. Patient 1. Patient was a 42-year-old woman with metastatic disease in multiple subcutaneous sites, lung, liver, spleen, and lymph nodes. She received irradiated transduced tumor cells and had vaccine-prim ed lymph node (VPLN) cells harvested 8 days later. She went on to receive approximately 2 3 10 1 0 activated VPLN cells intravenously along with the concomitant adm inistration of IL-2. After five doses of IL-2, treatm ent had to be discontinued because of hypotension and low urine output. This resolved after several days. Prior to discharge she became acutely comatose. A CT scan of the brain revealed a left temporal lobe intracerebral bleed. Because of the patient' s extensive metastatic disease the patient was allowed to expire. An autopsy was performed and she was found to have a small focus of metastatic disease in the brain, causing the bleed. The disease was occult since a pretreatm ent brain CT scan had been negative.
Summary of patients and immunological function
Functional immune studies of this patient' s VPLNs were performed. A tumor line was established and the patient was found to be MHC class I positive, but class II negative. Fractionated CD4 1 and CD8
1
T cell subpopulations were assessed for immune function. There was no cytokine release (IFN-g , GM-CSF, or IL-10) of these activated T cell populations in response to autologous tum or cells (data not shown).
Patient 2.
Patient 2 is a 57-year-old woman with metastatic melanom a to lung and mediastinal lymph nodes. She went on to receive 3 3 10 10 VPLN cells with 14 doses of IL-2. After 2 months of follow-up, CT scans revealed a partial response. She was retreated with a similar num ber of VPLN cells and IL-2 and went on to have a complete response of all evaluable disease (Fig. 3) . Approximately 4 months after her second treatment, she went on to receive 15 more doses of IL-2. She has remained in complete remission for 361 months. A cell line could not be established from this patient' s tumor and hence, functional immune studies were not performed. Her disease remained stable for 2 months, at which time it was decided to retreat her. During the period of VPLN cell activation for this second treatment, she developed sym ptom atic brain metastases and was taken off protocol.
We were able to establish a tum or line for functional immune studies of her VPLN cells. The tumor cell line expressed both MHC class I and II molecules. Fractionated CD4 1 and CD8 1 T cell subpopulations were examined for cytokine release. As shown in Fig. 4, the CD4 1 cells induced by the GM-CSF-transduced vaccine released IFN-g , GM-CSF, and IL-10 in response to autologous tum or cells. This response was relatively specific since an allogeneic tum or line failed to stimulate the same response. There was minimal cytokine released by CD8 1 T cells (Fig. 4) . The addition of blocking MAb demonstrated the response to be MHC class II restricted.
This patient was vaccinated with both WT and GM-CSFtransduced tumor cells. This allowed us to compare the immune function of WT and GM-CSF VPLN cells in response to autologous tumor. As summarized in Fig. 5 Patient 5. Patient 5 was a 46-year-old woman with metastatic disease involving lung, liver, and subcutaneous sites. During the time of transduction of tumor cells and subsequent vaccination, the patient developed rapidly progressive disease in her lungs. She had to be hospitalized for pneumonia prior to her planned cell infusion. Because of her subsequent poor performance status, it was felt she could not tolerate the cell infusion and IL-2 and was taken off the protocol.
A tumor line established from this patient expressed both MHC class I and II molecules. This patient was also vaccinated with WT and GM-CSF-transduced tum or cells, which permitted com parison of the different VPLN populations. Purified CD3 1 T cells were analyzed and are sum marized in Fig. 6 . Because of the limited number of VPLN cells, fractionation of CD4 A summary of the toxicities that were observed in the patients receiving activated VPLN cells plus IL-2 are presented in Table 2 . The toxicities were associated with the IL-2 administration and were reversible. The death of patient 1 was secondary to progressive disease.
DISCUSSION
Murine studies have demonstrated that GM-CSF-transduced tum or cells used as a vaccine can induce protective immunity to a subsequent challenge of tum or cells (Dranoff et al., 1993) . GM-CSF appears to be a potent immune adjuvant in the induction of T cell immunity, which has been postulated to be due to the recruitment of dendritic cells and/ or their activation as antigen-presenting cells. However, the use of cytokine-transduced tumor cells as vaccines to treat established tumors has been limited. There are only a few reports demonstrating that established tumors can be successfully treated by immunization with cytokine-secretin g tumor cells (Golumbek et al., 1991; Connor et al., 1993; Nagai et al., 1998) . Our laboratory has taken a different approach in treating established tum ors by employing ex vivo activated T cells for adoptive immunotherap y. These T cells are generated in vivo by active immunization with vaccines composed of tumor cells admixed with bacterial immune adjuvants or genetically modified tumor cells engineered to secrete cytokines. In a direct comparison, we found that GM-CSF secreted by tumor cells was superior to the use of a bacterial adjuvant in sensitizing T cells to tumor antigen in vivo (Arca et al., 1996a) . In these studies, we utilized the poorly immunogenic D5 melanom a line, from which we produced several stable GM-CSF-secreting clones by retroviral transduction. The D5 melanom a lacks both class I and II MHC molecules. We compared the GM-CSF transfectant with wild-type (WT) tumor admixed with Corynebacteriu m parvum in the induction of tumor-reactive T cells derived from lymph nodes draining the sites of intradermal vaccinations. These vaccine-primed lym ph node cells were subsequently activated in vitro by an anti-CD3/IL-2 method we have previously described, which allows expansion of the cells while maintaining their antitumor reactivity (Yoshizawa et al., 1991) . The antitumor reactivity of the VPLN cells was assessed in an adoptive immunotherapy model of established pulmonary metastases. GM-CSF-induced VPLN cells were significantly better than VPLN cells induced by the bacterial adjuvant in mediating tumor regression. When we examined other cytokines introduced into the D5 melanom a by gene transfer (i.e., IL-2, IFN-g , or IL-4), GM-CSF was superior in the induction of T cell immunity (Arca et al., 1996b) .
Our clinical trial demonstrated that a significant influx of dendritic cells was recruited to the site of the GM-CSF-secreting vaccine. This was a result of the local elaboration of cytokine since we also injected the WT vaccine as a control for com parative analysis in four patients. Three of the four patients had a greater influx of dendritic cells at the GM-CSF vaccine site com pared with the WT vaccine. In the one patient who did not manifest this finding, the vaccination was inoculated subcutaneously rather than intradermally as identified by immunohistochem ical analysis. We postulate that the location of vaccine inoculation may be important and that the dendritic cells migrate from the dermis into the vaccine sites.
Of more interest was the evaluation of immune function of the VPLN cells generated by the vaccines. There was a diversity of immune responses. Unfortunately, we were unable to enroll more patients in this study because of a limited supply of GM-CSF retroviral vector. Nonetheless, there were some interesting observations that may be useful in the design of future studies. In individual patients, we were able to measure different immune responses from regional nodes draining WT versus GM-CSF-secretin g tumor cell vaccination sites. In patient 4, CD4 1 T cells derived from the GM-CSF VPLN cells had significantly depressed IL-10 elaboration compared with WT VPLN cells. The secretion of IFN-g and GM-CSF was actually comparable between WT VPLN and GM-CSF VPLN cells in this same patient. In animal models, we have demonstrated that immune T cells that secrete type 2 cytokines (i.e., IL-10) have a suppressive interaction on antitumor reactivity when used in adoptive immunotherap y; where the elaboration of type 1 cytokines (i.e., IFN-g ) or GM-CSF can facilitate tumor regression . Hence, the generation of effector T cells with minimal IL-10 elaboration would be predicted to be clinically useful. In patient 5, we noted that CD3 1 T cells from GM-CSF VPLN had upregulated secretion of IFNg , GM-CSF, and IL-10 com pared with WT VPLN. This would suggest that the local elaboration of GM-CSF at the vaccine site had a significant adjuvant effect on several different T cell populations. We had insufficient numbers of cells from this patient to perform CD4 1 and CD8 1 T cell separations. In patient 1, we did not administer a control vaccine of WT tumor cells. However, the GM-CSF VPLN cells failed to secrete any detectable cytokines in response to autologous tumor, suggesting that there may have been host factors that caused an immune suppression.
The use of GM-CSF-transduced autologous tumor cells administered as a vaccine for the treatment of human cancer has been previously reported as a case report. Ellem et al. (1997) treated a patient with stage IV melanoma with multiple inoculations of autologous tumor cells genetically modified to secrete GM-CSF. A mixed tumor response was observed, and a strong delayed-type hypersensitivity reaction to autologous tumor cells identified. In the peripheral circulation, both a CD8 1 and CD4
1 cellular response to autologous tumor was observed over a transient period. As a case report, it is hard to draw definitive conclusions about the immunologic effects of this type CHANG ET AL. 848 of vaccine. Nevertheless, this case demonstrated increased immune reactivity of PBLs to autologous tum or over the course of several immunizations . As suggested by our data, the immune reactivity can be different betw een patients because of diverse clinical factors. Correlative studies with larger num bers of patients need to be performed in order to identify which immune param eters can predict the therapeutic efficacy of a particular vaccine approach.
The role of GM-CSF secreted locally at the tumor vaccination site may mediate its regional immune adjuvant effect by several mechanisms. Our data strongly suggest that recruitment of DCs occurs within the vaccine site as a result of GM-CSF protein secretion. Hence, the presence of increased numbers of DCs may result in increased antigen processing and presentation locally. We have also documented in a preclinical study that there is an associated migration of DCs to the immediate draining lymph nodes when tumor vaccination involves GM-CSF as an adjuvant elaborated locally in the skin (Tanigawa et al., 2000) . Another mechanism by which GM-CSF may act as an effective adjuvant is by correction of any suppressed antigen-presenting capacity that has been observed in the cancerbearing host. We have previously observed that dermal DCs in hum an basal cell and squamous cell carcinomas fail to express important costimulatory molecules (i.e., CD80 and CD86) and have defective antigen-presenting capacity, which could be corrected by the exposure to GM-CSF (Nestle et al., 1997a,b) .
Soluble GM-CSF has been used as an adjuvant with an autologous tumor cell vaccine in patients with metastatic melanoma. Leong et al. reported the use of soluble GM-CSF inoculated intraderma lly over the course of several days at vaccine sites composed of autologous tum or cells and bacillus Calm ette-G uérin (BCG) (Leong et al., 1999) . In that study 4 of 20 patients were docum ented to have com plete or partial responses. Immunologic data to measure cellular responses to tumor were not assessed. Even though a separate cohort of patients vaccinated with tumor cells and BCG had no clinical responses, the contributio n of GM-CSF cannot be assumed since it was not a prospective , randomize d trial. However, it did suggest that GM-CSF may be an important local adjuvant in the induction of tumor regression responses. The advantage of utilizing genetically modified tum or cells, as opposed to soluble cytokine protein, is the avoidance of multiple injections.
One conclusion we can draw from this experience is that GM-CSF appears to be elaborated locally as indicated by the dendritic cell infiltration, and that it results in a larger accumulation of lym phoid cells in the immediate draining lym ph node basin. Furtherm ore, our data indicate that the local elaboration of GM-CSF can influence the sensitization of tum or reactive T cells in the draining LN. The one com plete tumor response we have observed in the patients we have treated suggests that this may provide a method to generate tumor-reactive T cells capable of mediating regression of established tumor metastases. We cannot exclude the possibility that the tumor response that was observed was due to the IL-2 adm inistration. A phase II trial needs to be conducted to ascertain what response rate is associated with this therapy in order to determine if a randomized trial comparing IL-2 treatment alone is justified. We are currently evaluating gene gun methods to introduce GM-CSF plasmid into tumor cells as a simpler way to generate vaccine-primed lymph nodes that might be applied in a phase II study (Tanigawa et al., 2000) .
